Quality of life in primary sclerosing cholangitis: a systematic review

被引:7
|
作者
Marcus, Elena [1 ,2 ]
Stone, Paddy [1 ]
Krooupa, Anna-Maria [1 ]
Thorburn, Douglas [2 ,3 ]
Vivat, Bella [1 ]
机构
[1] UCL, Marie Curie Palliat Care Res Dept, Div Psychiat, 6th Floor,Maple House,149 Tottenham Court Rd, London W1T 7NF, England
[2] UCL, Royal Free Hosp, Inst Liver & Digest Hlth, UCL Royal Free Campus, London, England
[3] Royal Free Hosp, Sheila Sherlock Liver Unit, London, England
关键词
Primary sclerosing cholangitis; Quality of life; Questionnaires; INFLAMMATORY-BOWEL-DISEASE; CHOLESTATIC LIVER-DISEASES; PRIMARY BILIARY-CIRRHOSIS; POUCH-ANAL ANASTOMOSIS; CLINICAL-TRIAL; VALIDATION; FATIGUE; RISK; VANCOMYCIN; MANAGEMENT;
D O I
10.1186/s12955-021-01739-3
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundPrimary sclerosing cholangitis (PSC) is a rare bile duct and liver disease which can considerably impact quality of life (QoL). As part of a project developing a measure of QoL for people with PSC, we conducted a systematic review with four review questions. The first of these questions overlaps with a recently published systematic review, so this paper reports on the last three of our initial four questions: (A) How does QoL in PSC compare with other groups?, (B) Which attributes/factors are associated with impaired QoL in PSC?, (C) Which interventions are effective in improving QoL in people with PSC?.MethodsWe systematically searched five databases from inception to 1 November 2020 and assessed the methodological quality of included studies using standard checklists.ResultsWe identified 28 studies: 17 for (A), ten for (B), and nine for (C). Limited evidence was found for all review questions, with few studies included in each comparison, and small sample sizes. The limited evidence available indicated poorer QoL for people with PSC compared with healthy controls, but findings were mixed for comparisons with the general population. QoL outcomes in PSC were comparable to other chronic conditions. Itch, pain, jaundice, severity of inflammatory bowel disease, liver cirrhosis, and large-duct PSC were all associated with impaired QoL. No associations were found between QoL and PSC severity measured with surrogate markers of disease progression or one of three prognostic scoring systems. No interventions were found to improve QoL outcomes.ConclusionThe limited findings from included studies suggest that markers of disease progression used in clinical trials may not reflect the experiences of people with PSC. This highlights the importance for clinical research studies to assess QoL alongside clinical and laboratory-based outcomes. A valid and responsive PSC-specific measure of QoL, to adequately capture all issues of importance to people with PSC, would therefore be helpful for clinical research studies.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Health-related quality of life among patients with primary sclerosing cholangitis
    Haapamaki, Johanna
    Tenca, Andrea
    Sintonen, Harri
    Barner-Rasmussen, Nina
    Farkkila, Martti A.
    LIVER INTERNATIONAL, 2015, 35 (09) : 2194 - 2201
  • [22] Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Shah, Ayesha
    Crawford, Darrel
    Burger, Daniel
    Martin, Neal
    Walker, Marjorie
    Talley, Nicholas J.
    Tallis, Caroline
    Jones, Michael
    Stuart, Katherine
    Keely, Simon
    Lewindon, Peter
    Macdonald, Graeme A.
    Morrison, Mark
    Holtmann, Gerald J.
    SEMINARS IN LIVER DISEASE, 2019, 39 (04) : 432 - 441
  • [23] Patient-reported quality of care in primary sclerosing cholangitis
    Walmsley, Martine
    Tornai, David
    Cazzagon, Nora
    Leburgue, Angela
    Mrzljak, Anna
    Lenzen, Henrike
    Carbone, Marco
    Madaleno, Joao
    Lleo, Ana
    Junge, Norman
    Schramm, Christoph
    Bergquist, Annika
    LIVER INTERNATIONAL, 2023, 43 (08) : 1654 - 1662
  • [24] Update on primary sclerosing cholangitis
    Karlsen, Tom H.
    Schrumpf, Erik
    Boberg, Kirsten M.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 (06) : 390 - 400
  • [25] The immunobiology of primary sclerosing cholangitis
    Aron, Jonathan H.
    Bowlus, Christopher L.
    SEMINARS IN IMMUNOPATHOLOGY, 2009, 31 (03) : 383 - 397
  • [26] A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis
    Wittek, Agnes
    Steglich, Babett
    Casar, Christian
    Seiz, Oliver
    Huber, Philipp
    Ehlken, Hanno
    Reher, Dominik
    Wende, Sandra
    Bedke, Tanja
    Kempski, Jan
    Boettcher, Marius
    Bang, Corinna
    Thingholm, Louise
    Krech, Till
    Lohse, Ansgar W.
    Sauter, Guido
    Roesch, Thomas
    Franke, Andre
    Schramm, Christoph
    Gagliani, Nicola
    Pelczar, Penelope
    Huber, Samuel
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (06) : 900 - 910
  • [27] Gut microbiome in primary sclerosing cholangitis: A review
    Little, Rebecca
    Wine, Eytan
    Kamath, Binita M.
    Griffiths, Anne M.
    Ricciuto, Amanda
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (21) : 2768 - 2780
  • [28] Immunogenetics in primary sclerosing cholangitis
    Chung, Brian K.
    Hirschfield, Gideon M.
    CURRENT OPINION IN GASTROENTEROLOGY, 2017, 33 (02) : 93 - 98
  • [29] Review of pharmacotherapeutic treatments for primary sclerosing cholangitis
    Zhang, Chaoran
    Hussaini, Trana
    Yoshida, Eric M.
    CANADIAN LIVER JOURNAL, 2019, 2 (03): : 58 - 70
  • [30] Gut microbiome in primary sclerosing cholangitis: A review
    Rebecca Little
    Eytan Wine
    Binita M Kamath
    Anne M Griffiths
    Amanda Ricciuto
    World Journal of Gastroenterology, 2020, 26 (21) : 2768 - 2780